ADVFN - Advanced Financial Network.
HOME» AMEX » P » PLX Stock Price » PLX Stock News

Protalix Biotherapeutics Share News

 Protalix Biotherapeutics, Stock Price
PLX Stock Price
 Protalix Biotherapeutics, Stock Chart
PLX Stock Chart
 Protalix Biotherapeutics, Stock News
PLX Stock News
 Protalix Biotherapeutics, Company Information
PLX Company Information
 Protalix Biotherapeutics, Stock Trades
PLX Stock Trades

Protalix Gets $25 Million Milestone Payment For Rare-Disease Drug

By Kristin Jones Protalix BioTherapeutics Inc. (PLX) has received a $25 million milestone payment from Pfizer Inc. (PFE) after the U.S. Food and Drug Administration approved its new drug for the treatment of Gaucher disease. On May 1, U.S. regulators approved taliglucerase alfa, sold as Elelyso, for the treatment of type 1 Gaucher disease, a genetic disorder that can cause enlargement of the spleen and liver, as well as lung disease and bone problems. Pfizer and Protaliz entered an exclusive agreement for the development and commercialization of Elelyso in November 2009. Under the terms of the deal, Pfizer has an exclusive license to sell Elelyso, except in Israel. Elelyso, an infusion administered by health-care professionals every other week, is the first plant-derived cell-based enzyme replacement. It will compete in the U.S. with the Gaucher-disease treatment Cerezyme, produced by Genzyme, the U.S. biotechnology unit of Sanofi S.A. (SNY, SAN.FR) and Shire PLC's (SHPGY, SHP.LN) Vpriv. Protalix shares rose 2.4% to $6.85 in premarket trading. The stock is up 36% so far this year. Write to Kristin Jones at [email protected]

Stock News for Protalix Biotherapeutics (PLX)
DateTimeHeadline
03/16/201716:23:01Proxy Statement (definitive) (def 14a)
03/16/201716:10:46Annual Report (10-k)
03/16/201708:09:54Current Report Filing (8-k)
03/06/201716:16:44Proxy Statement - Notice of Shareholders Meeting (preliminary...
02/23/201717:26:47Amended Statement of Ownership (sc 13g/a)
02/16/201716:32:38Current Report Filing (8-k)
02/15/201712:24:31Amended Statement of Ownership (sc 13g/a)
02/15/201712:21:51Statement of Ownership (sc 13g)
02/14/201718:12:28Statement of Ownership (sc 13g)
02/14/201718:11:33Current Report Filing (8-k)
02/14/201718:10:07Current Report Filing (8-k)
02/14/201712:02:49Amended Statement of Ownership (sc 13g/a)
02/14/201711:48:41Amended Statement of Ownership (sc 13g/a)
02/14/201710:27:37Amended Statement of Ownership (sc 13g/a)
02/01/201717:03:02Statement of Ownership (sc 13g)
01/09/201706:13:02Current Report Filing (8-k)
01/04/201710:56:33Amended Statement of Ownership (sc 13g/a)
01/03/201707:40:22Current Report Filing (8-k)
12/27/201607:39:52Current Report Filing (8-k)
12/23/201616:16:52Statement of Ownership (sc 13g)

Protalix Biotherapeutics and other American Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US